For citations:
Nasonov E.L., Mazurov V.I., Lila A.M., Dubinina T.V., Gaydukova I.Z., Lapshina S.A., Klimenko A.A., Somov D.V., Lukianov S.A., Chudakov D.M., Zvyagin I.V., Britanova O.V., Korolev M.A., Abdulganieva D.I., Krechikova D.G., Kastanayan A.A., Eliseeva L.V., Samigullina R.R., Povarova T.V., Antipova O.V., Smakotina S.A., Soboleva V.N., Nesmeyanova O.B., Plaksina T.V., Soroka N.F., Vinogradova I.B., Rebrov A.P., Kropotina T.V., Maslyanskiy A.L., Zinkina-Orikhan A.V., Lin’kova Yu.N., Pukhtinskaia P.S., Morozova M.A., Vinderskaya G.A. Effectiveness and safety of BCD180, anti-TRBV9+ T-lymphocytes monoclonal antibody in patients with active radiographic axial spondyloarthritis: 36-week results of double-blind randomized placebo-controlled phase II clinical study ELEFTA. Rheumatology Science and Practice. 2024;62(1):65-80. (In Russ.) https://doi.org/10.47360/1995-4484-2024-65-80
Email this article 